It has previously been reported that synthetic peptides correspondg to sequences derived from T-cell receptor variable regions identified as dominant in the T-cellmediated autoimmune disease experimental allergic encephalomyclitis in both the mouse and the rat can down-regulate disease in Lewis rats. In contrast to these results, we have found that immunization of Lewis rats with such peptides in complete Freund's adjuvant prior to induction of experimental allergic encephalomyelitis with myelin basic protein leads to responses ranging from profound disease enhancement to lack of disease. In some cases, enhanced disease was followed by a prolonged neurologic deficit that resembles multiple sclerosis more closely than does acipte experimental allergic encephalomyelitis. These findings, on the one hand, support previous results showing T-cell receptor peptide-induced modulation of the disease experimental allergic encephalomyelitis and, on the other, indicate that such immunization is not a reliable method for inducing suppression of encephalitogenic effector cells.
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The finding that a limited set ofT cells, in the mouse (1-3) and the rat (4, 5) , mediates the autoimmune disease of the central nervous system experimental allergic encephalomyelitis (EAE) suggests the possibility of immune intervention by clonal-specific regulation. In both species, T cells bearing the T-cell receptor (TCR) variable (V) regions V(88.2 and Va2/4 are the dominant disease-causing population (6) . Monoclonal antibodies directed against these TCR V regions have been shown to block the expression of EAE in response to myelin basic protein (MBP) in Lewis rats (7) , and similar antibodies have both blocked disease and suppressed ongoing disease in mice (1) (2) (3) . Recently, evidence of disease suppression in rats after immunization with synthetic peptides corresponding to portions of the V a and V a chains of identified autoreactive T-cell clones has been seen (8, 9) . We now report that immunization of Lewis rats with peptides representing the V regions ofthese dominant TCRs can hasten disease onset and increase the severity and duration of disease.
We constructed three peptides derived from both TCR chains of the T-cell hybridoma 5.10, which is specific for the encephalitogenic determinant of MBP (4): the Ja39 peptide with the sequence RFGAGTRLTVK (8), the CDR2-Vf8 peptide with the sequence DMGHGLRLIHYSYDVN-STEKG (9) , and TK20 representing the N-terminal residues 5-24 of rat Vf38.2 (4) with the sequence TQSPRNKVALTG-GKVTLSCK. Rats were immunized with these peptides in complete Freund's adjuvant (CFA) prior to induction of EAE with MBP, and responses ranging from profound disease enhancement to the lack of disease were obtained. In some cases, enhancement of disease was followed by a prolonged neurologic deficit, something we have not previously observed in MBP-induced EAE, which is generally an acute self-limiting disease. This chronic condition is of considerable interest in that it more closely resembles multiple sclerosis than does the acute form of EAE, presently the most generally used animal model for that disorder. This report, then, describes a model for multiple sclerosis using MBP as the immunogen. Lack of a measurable T-cell or antibody response to the peptide has led us to consider the possibility that a regulatory cell normally functioning in EAE that is able to limit the disease in vivo has been tolerized.
MATERIALS AND METHODS
Animals. Eight-week-old female Lewis rats were purchased from the Charles River Breeding Laboratories and maintained in the animal facility of The Wistar Institute. EAE Induction. MBP was dissolved in saline and emulsified with an equal volume of CFA containing Mycobacterium tuberculosis (H37Ra) at 2 mg/ml (Difco). Rats were injected subcutaneously in the thigh with a total volume of 100 ILI containing 50 1g of MBP. Animals were observed for clinical signs of EAE. In experiments 1-3 (see Table 1 ), the observations were made by an observer without knowledge of the immunization protocol. Disease severity was recorded daily using the following paralysis scale: 1, tail paralysis; 2, hind limb weakness and/or partial paralysis; 3, hind limb paralysis; 4 (14) and modified by Hickey et al. (10) . Peptide Synthesis. Peptide synthesis was done on a Biosearch model SAM2 peptide synthesizer using a combination of fluoren-9-ylmethoxycarbonyl-amino acid symmetrical anhydrides and pentafluorophenyl esters for the acylation reactions. Cleavage from the solid support was achieved with trifluoroacetic acid. The CDR2-V.38 peptide was dialyzed in tubing with a Mr 1000 cutoff and purified on an Altex Ultrasphere ODS reversed-phase HPLC column. The isolated peak was subjected to positive-ion fast atom bombardment/mass spectrum analysis, which revealed a single ion at 2392 mass units as predicted. This analysis and amino acid analysis showed purity and the appropriate amino acid comAbbreviations: EAE, experimental allergic encephalomyelitis; CFA, complete Freund's adjuvant; MBP, myelin basic protein; TCR, T-cell receptor; V region, variable region.
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Peptide Immunization. TCR peptides were dissolved in PBS and emulsified with an equal volume of CFA containing M. tuberculosis (H37Ra) at 1 mg/ml. Unless otherwise indicated, each animal was injected subcutaneously in both hind foot pads with a total of 100 pug of peptide in 200 A.l of emulsion.
RESULTS
Lewis rats were injected with CFA or CFA plus the CDR2-Vfi8 peptide (9) in the rear footpads (see Table 1 (9) , but in fact showed a higher average disease level and, possibly more important, earlier onset of disease. The third animal showed no effect of the peptide treatment, the time of onset and level of disease being indistinguishable from that in the controls (Table 1 , experiment 1, and Fig. 1A ). The two animals that showed enhanced disease also developed a chronic disease state, unusual in rats receiving MBP: one animal displayed a flaccid tail that never improved and the other, which initially displayed typical fore and hind limb paralysis, had improved by day 16 but then went on to develop severe asymmetric clonus. Enhanced disease severity and development of chronic disease were also seen in one rat given the CDR2-VP8 peptide 2.5 months prior to the challenge with MBP in CFA ( Table 1, experiment 2) .
To determine whether these effects were due to the particular peptide used for immunization, we repeated these experiments with each of the three TCR peptides. Immunization with the CDR2-Vp8 peptide followed by MBP again resulted in severe disease with early onset (Table 1 and Fig.  2) . Similar results were obtained with the Ja39 peptide. Although disease was slightly more severe in rats immunized with the TK20'peptide than in the 'controls, the time of onset did not differ. It should be pointed out that in some cases the controls did exhibit a less-severe EAE than 'is generally reported, due to the fact that the MBP in CFA-had been given in the thigh where it is generally less encephalitogenic.
Nevertheless, the CR2-V.88 and Ja39 peptides cause early onset of disease with dramatic enhancement over control levels and with low levels of disease in the controls. To exclude the possibility that our results ' impurity in the peptide preparations, an I CDR2-Vj38 peptide was used to immunize the experiment 4, and Fig. 3 ). In this experimei developed chronic disease, one developed self and the third remained healthy.
Besides following clinical symptoms and also examined sera from the peptide-immunize ability to bind to 5.10, the MBP-(68-88)-spec bridoma from whose TCR sequences the I derived. As can be seen in the flow cytometry 4, there was no binding activity in any of the from rats immunized with the TCR peptide foIl (from animals in experiment 3) or TCR peptide (data not shown) as compared to rats immun CFA followed by MBP (Fig. 4B) , though the expression on the cell surface of the hybridon determined by the binding of R73, an anti-TC antibody (11) (Fig. 4A) TCR-derived self antigens frequently leads to enhancement of EAE. In 9 of 12 animals injected with the previously tested peptide CDR2-Vf38 (Table 2) , profound enhancement of 25 30 disease was observed, whereas in 2 of 12 animals no effect was seen and only 1 of 12 animals showed no signs of disease, which could be the same as the reported suppression (9) .
BP-induced EAE Enhancement of disease in TCR peptide-primed animals in )R2-V/38 peptide these experiments was manifested not only as a greater :h later, rats were average state of disease as measured by a subjective judged for individual ment on a standard paralysis scale but also as a significant shift (2-5 days) of the kinetics curves to the left, to an earlier onset of severe disease. Since early onset has historically were due to an been taken as the sine qua non of second-set responses in HPLC-purified graft rejection as well as in antibody titers, we believe that rats (Table 1, this shift is clear evidence of a second-set response. Further nt, one animal evidence of a qualitatively different disease state lies in the F-limiting EAE, fact that 50% of the animals developed chronic disease, a phenomenon not often seen in animals receiving MBP alone. pathology, we EAE has historically been used as an animal model of cd ratsfor their multiple sclerosis due to the similarities between the two pific T-cell hy-conditions. The most commonly studied form of EAE, howpeptides were ever, is an acute self-limiting condition that confers resisprofiles in Fig. tance to reinduction of active disease. These characteristics e sera derived contrast sharply with the clinical course of multiple sclerosis, lowed by MBP which is typically seen as a chronic illness with exacerbations -in CFA alone and remissions over many years. be activated to positively stimulate the EAE effector cell. Finally, it is also possible that some unknown stochastic process predisposes individuals to enhancement, suppression, or lack ofeffect from immunization with these peptides.
